Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (31-40 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PRobert J Kreitman, Raffit Hassan, David J Fitzgerald, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 6, 2005
Localization of mesothelin in epithelial ovarian cancerRaffit Hassan, Robert J Kreitman, Ira Pastan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenograftsRaffit Hassan, V Courtney Broaddus, Shannon Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1Raffit Hassan, Juanita Williams-Gould, Thelma Watson, et al.
Frontiers in Oncology|April 1, 2020
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?Luca Cantini, Raffit Hassan, Daniel H Sterman, et al.
European Journal of Immunology|May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumorsLuigi Grasso, Qun Jiang, Raffit Hassan, et al.
American Journal of Clinical Pathology|January 19, 2006
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitisRaffit Hassan, Zoltan G Laszik, Megan Lerner, et al.
Oncology (Williston Park, N.Y.)|November 16, 2005
Update on malignant mesotheliomaKaren Antman, Raffit Hassan, Milton Eisner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2020
Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two CasesMichel S Kabbash, Joseph Edmund, Azam Ghafoor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2006
Mesothelin is shed from tumor cellsMitchell Ho, Masanori Onda, Qing-Cheng Wang, et al.
Pageof 15

Showing results (31-40 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PRobert J Kreitman, Raffit Hassan, David J Fitzgerald, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 6, 2005
Localization of mesothelin in epithelial ovarian cancerRaffit Hassan, Robert J Kreitman, Ira Pastan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenograftsRaffit Hassan, V Courtney Broaddus, Shannon Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1Raffit Hassan, Juanita Williams-Gould, Thelma Watson, et al.
Frontiers in Oncology|April 1, 2020
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?Luca Cantini, Raffit Hassan, Daniel H Sterman, et al.
European Journal of Immunology|May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumorsLuigi Grasso, Qun Jiang, Raffit Hassan, et al.
American Journal of Clinical Pathology|January 19, 2006
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitisRaffit Hassan, Zoltan G Laszik, Megan Lerner, et al.
Oncology (Williston Park, N.Y.)|November 16, 2005
Update on malignant mesotheliomaKaren Antman, Raffit Hassan, Milton Eisner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2020
Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two CasesMichel S Kabbash, Joseph Edmund, Azam Ghafoor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 21, 2006
Mesothelin is shed from tumor cellsMitchell Ho, Masanori Onda, Qing-Cheng Wang, et al.
Pageof 15